N.V. “announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific ...

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an ...

Merus N.V. (MRUS) stock surges after interim trial data from a cancer trial for the company's lead asset, petosemtamab with ...

ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy.

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...

As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running ...

The findings will be presented at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)• Dana-Farber ...

Shares of Merus jumped after the company posted positive interim data from a trial of its treatment for head and neck cancer. The stock rose 31% to $54.49 on Friday. Shares have climbed 24% over the ...

CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatelli ...

Merus N.V. (NASDAQ: MRUS) shares are trading higher Friday after the company reported promising interim results from its ...